---
title: "Zomedica (ZOM.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ZOM.US.md"
symbol: "ZOM.US"
name: "Zomedica"
industry: "Health Care Equipment"
datetime: "2026-04-15T11:27:19.678Z"
locales:
  - [en](https://longbridge.com/en/quote/ZOM.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ZOM.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ZOM.US.md)
---

# Zomedica (ZOM.US)

## Company Overview

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc.

| Item | Detail |
|------|--------|
| Industry | Health Care Equipment |
| Exchange | US Market |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-15T04:30:17.000Z

**Overall: C (0.55)**

**Industry**: Health Care Equipment

| Metric | Value |
|--------|-------|
| Industry Ranking | 131 / 182 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 11.33% |  |
| Net Profit YoY | -316.51% |  |
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 0.00 |  |
| Revenue | 26727000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -26.82% | E |
| Profit Margin | -232.70% | E |
| Gross Margin | 72.32% | A |
| Revenue YoY | 11.33% | B |
| Net Profit YoY | -316.51% | E |
| Total Assets YoY | -22.15% | E |
| Net Assets YoY | -22.25% | E |
| Cash Flow Margin | -42.97% | E |
| OCF YoY | 11.33% | B |
| Turnover | 0.11 | E |
| Gearing Ratio | 5.26% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Zomedica",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "11.33%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-316.51%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "26727000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-26.82%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-232.70%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "72.32%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "11.33%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "-316.51%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-22.15%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-22.25%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-42.97%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "11.33%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.11",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "5.26%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Delcath (DCTH.US) | C | A | B | A | A | A |
| 02 | Abbott Laboratories (ABT.US) | B | C | C | C | B | B |
| 03 | Intuitive Surgical (ISRG.US) | A | B | C | A | B | B |
| 04 | Stryker (SYK.US) | A | B | C | C | B | B |
| 05 | Boston Scientific (BSX.US) | B | B | C | C | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ZOM.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ZOM.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ZOM.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ZOM.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**